

# Tongtong An

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9892030/tongtong-an-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31  
papers

394  
citations

9  
h-index

19  
g-index

35  
ext. papers

577  
ext. citations

4.6  
avg, IF

2.91  
L-index

#	Paper	IF	Citations
31	Significant Upregulation of HERV-K (HML-2) Transcription Levels in Human Lung Cancer and Cancer Cells.. <i>Frontiers in Microbiology</i> , <b>2022</b> , 13, 850444	5.7	1
30	A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1/2 study. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	1
29	Toripalimab in an advanced non-small cell lung cancer patient with poor general condition after multiline treatment: a case report. <i>Journal of International Medical Research</i> , <b>2021</b> , 49, 3000605211042988	1.4	0
28	Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting. <i>Journal of Thoracic Disease</i> , <b>2021</b> , 13, 1813-1821	2.6	0
27	Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma-A Retrospective Analysis of a Multicenter Clinical Study. <i>Frontiers in Molecular Biosciences</i> , <b>2021</b> , 8, 639892	5.6	5
26	Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients. <i>Annals of Translational Medicine</i> , <b>2021</b> , 9, 33	3.2	7
25	Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectrometry analysis with parallel reaction monitoring (PRM) verification. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 981-994	4.4	4
24	Evaluation of different treatment strategies between right-sided and left-sided pneumonectomy for stage I-IIIa non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , <b>2021</b> , 13, 1799-1812	2.6	0
23	Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients. <i>Cancer Cell International</i> , <b>2020</b> , 20, 590	6.4	
22	Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 1149-1159	3.2	2
21	Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 626	5.3	5
20	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 892-901	12.9	34
19	A nomogram model to predict death rate among non-small cell lung cancer (NSCLC) patients with surgery in surveillance, epidemiology, and end results (SEER) database. <i>BMC Cancer</i> , <b>2020</b> , 20, 666	4.8	8
18	Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1137	5.3	3
17	Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis. <i>BMC Cancer</i> , <b>2020</b> , 20, 793	4.8	6
16	Characterization of Microbiota in Cancerous Lung and the Contralateral Non-Cancerous Lung Within Lung Cancer Patients. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1584	5.3	1
15	Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5049-5060	12.9	31

14	Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 1193-1202	3.2	4
13	Nomogram to predict cause-specific mortality in extensive-stage small cell lung cancer: A competing risk analysis. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 1788-1797	3.2	5
12	Optimal first-line treatment for advanced thymic carcinoma. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 2081-2087	3.2	6
11	ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 2088-2095	3.2	14
10	Survival comparison of right and left side non-small cell lung cancer in stage I-IIIa patients: A Surveillance Epidemiology and End Results (SEER) analysis. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 459-471	3.2	8
9	Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases. <i>Cancer Research</i> , <b>2019</b> , 79, 7-20	10.1	63
8	Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel $\alpha_1$ Subunit-mediated Chemotherapy Resistance in Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2148-2158	12.9	29
7	Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 291-297	3.2	4
6	Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 1166-1173	3.2	7
5	Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1376-1387	8.9	29
4	Survival difference between Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , <b>2017</b> , 29, 553-560	3.8	10
3	Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1766-1778	8.9	35
2	A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , <b>2016</b> , 28, 12-8	3.8	1
1	Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 20810-24	3.3	63